Characterization of AUCs from sparsely sampled populations in toxicology studies

Pharmaceutical Research

Volumn 13, Issue 9, 1996, Pages 1283-1290

  Pai, Sudhakar M ^a   Fettner, Scott H ^a   Hajian, Gerald ^a   Cayen, Mitchell N ^a   Batra, Vijay K ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

pharmacokinetics; sparse sampling; toxicokinetics; toxicology

Indexed keywords

DRUG METABOLITE; FELBAMATE; LORATADINE;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; INTOXICATION; NONHUMAN; PHARMACOKINETICS; PRIORITY JOURNAL; RAT; STEADY STATE;

EID: 0029856273     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1016097227603     Document Type: Article

References (19)

1. J. Heykants and W. Meuldermans. Nonclinical kinetics and metabolism studies in the safety assessment of drugs. Drug Information Journal, 28:163-172 (1994).
2. M. N. Cayen. Considerations in the design of toxicokinetic studies. Toxicologic Pathology, 23:148-157 (1995).
3. ICH/EFPIA Safety Task Force on Toxicokinetics. Note for Guidance on Toxicokinetics. Draft No. 7 (1992).
4. Unpublished data on file. Department of Drug Metabolism and Pharmacokinetics. Schering-Plough Research Institute, Kenilworth, NJ.
5. Unpublished data on file. Department of Drug Metabolism and Pharmacokinetics. Schering-Plough Research Institute, Kenilworth, NJ.
6. J. Hempenius, G. Hendriks, J. Hingstman, C. K. Mensink, J. H. G. Jonkman, and C. C. Lin. An automated analytical method for the determination of felbamate in human plasma by robotic sample preparation and reversed-phase high performance liquid chromatography. J. Pharm. Biomed. Anal. 12 (1994).
7. R. Johnson, J. Christensen, and C. C. Lin. Sensitive gas-liquid chromatographic method for the determination of loratadine and its major active metabolite, descarboethoxyloratadine in human plasma using a nitrogen-phosphorus (N/P) detector. J. Chromatogr. B. 657:125-131 (1994).
8. M. Gibaldi and D. Perrier. Pharmacokinetics, 2nd edition, Marcel Dekker, New York, 1982, pp. 409-417, 445-449.
9. PCNONLIN, Version 4.0. Statistical Consultants Inc. Lexington, KY (1992).
10. A. Akaike. Posterior probabilities for choosing a regression model, Annals of the Institute of Mathematical Statistics, 30(A):9-14 (1978).
11. SAS. Statistical Institute Inc., Cary, NC. SAS Language: Reference, version 6, 1st edition, pp. 589 (1990).
12. H. Boxenbaum and M. Battle. Effective half-life in clinical pharmacology. J. Clin. Pharmacol. 35:763-766 (1995).
13. M. Gibaldi and D. Perrier. Pharmacokinetics, 2nd Edition, Marcel Dekker, New York, 1982, pp. 451-457.
14. B. Efron and R. J. Tihshirani. An Introduction to the Bootstrap. Chapman & Hall, New York, 1993.
15. H. Mager and G. Göller. Analysis of pseudo-profiles in organ pharmacokinetics and toxicokinetics. Statistics in Medicine. 14:1009-1024 (1995).
16. T. M. Ludden. Population pharmacokinetics. J. Clin. Pharmacol. 28:1059-1063 (1988).
17. B. Whiting, A. W. Kelman, and J. Grevel. Population pharmacokinetics: Theory and clinical applications. Clin. Pharmacokinet. 11:387-401 (1986).
18. F. Mentre, P. Burtin, Y. Merle, J. V. Bree, A. Mallet, and J-L. Steimer. Sparse-sampling optimal designs in pharmacokinetics and toxicokinetics. Drug Information Journal, 29:997-1019 (1995).
19. J. V. Bree, J. Nedelman, J-L. Steimer, F. Tse, W. Robinson, and W. Niederberger. Application of sparse sampling approaches in rodent toxicokinetics: A prospective view. Drug Information Journal, 28:263-279 (1994).